# The Efficacy of Azvudine and Paxlovid in High-risk Patients With COVID-19: A Prospective Randomized Controlled Trial

> **NCT05642910** · NA · UNKNOWN · sponsor: **Southeast University, China** · enrollment: 540 (estimated)

## Conditions studied

- SARS-CoV-2 Infection

## Interventions

- **DRUG:** Azvudine
- **DRUG:** Paxlovid group

## Key facts

- **NCT ID:** NCT05642910
- **Lead sponsor:** Southeast University, China
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-10-18
- **Primary completion:** 2023-01-31
- **Final completion:** 2023-04-30
- **Target enrollment:** 540 (ESTIMATED)
- **Last updated:** 2022-12-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05642910

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05642910, "The Efficacy of Azvudine and Paxlovid in High-risk Patients With COVID-19: A Prospective Randomized Controlled Trial". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05642910. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*